Immuneering Corporation
IMRX
$1.45
-$0.01-0.69%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.97% | -5.66% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.50% | 2.41% | |||
| Operating Income | -21.50% | -2.41% | |||
| Income Before Tax | -23.66% | -3.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.66% | -3.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.66% | -3.68% | |||
| EBIT | -21.50% | -2.41% | |||
| EBITDA | -21.66% | -2.44% | |||
| EPS Basic | -18.85% | -3.03% | |||
| Normalized Basic EPS | -17.80% | -3.91% | |||
| EPS Diluted | -18.85% | -3.03% | |||
| Normalized Diluted EPS | -17.80% | -3.91% | |||
| Average Basic Shares Outstanding | 4.05% | 0.64% | |||
| Average Diluted Shares Outstanding | 4.05% | 0.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||